By Raechel Thankam Job and Yadarisa Shabong Aug 17 (Reuters) - AstraZeneca said it is ending a late-stage trial that combined ...

Reports of preliminary talks between AstraZeneca and Bristol Myers Squibb moved shares and reignited debate over Big Pharma consolidation.

Futures are trading lower as we enter the final week of August, after a big risk-on Friday when traders and investors shook ...

Aug 17 (Reuters) - AstraZeneca is discontinuing a late-stage trial that tested experimental drug volrustomig plus ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported positive results from a late-stage trial of a two-drug combination for a ...

AstraZeneca PLC (NYSE:AZN) investors received a reassuring earnings report at a sensitive point in the company’s growth story ...

This is an industry that is as important to the country as the aerospace industry, as the automotive industry,’ says Jim ...

U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.

AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., ...

An interim data check revealed that survival goals were likely to be missed by volrustomig, one in a list of new drugs the ...

Admittedly, it's not uncommon for an acquirer's stock to fall upon announcement of a megamerger. After all, if an acquirer is paying for the stock with its own shares, it creates the opportunity for ...

Shares of Bristol Myers Squibb ( BMY) were up over 4% in premarket trading to their highest point since early 2023 following a report that the company held merger talks with AstraZeneca ( AZN ), ...